TD Cowen analyst Brendan Smith maintained a Buy rating on OmniAb yesterday and set a price target of $3.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brendan Smith has given his Buy rating due to a combination of factors including the introduction of OmniAb’s new OmniUltra technology. This innovative platform offers significant flexibility in antibody discovery and design, potentially setting OmniAb apart from competitors by enabling the production of ultralong CDRH3 antibodies. The technology is expected to enhance OmniAb’s capabilities and broaden its applicability in various fields such as bispecifics and CAR-T therapies.
Despite a reduction in revenue guidance for FY25 due to delays in partner programs, Smith notes that the company’s operational expense reductions and the positive outlook for the xPloration launch could drive growth in 2026 and beyond. The management’s efforts to streamline operations and control expenses, alongside the potential for increased interest in OmniAb’s technology as new pharma budgets are set, contribute to the optimistic Buy rating.